DMAA Drugs Made In America Acquisition Corp.
Blank Checks · Nasdaq · SEC CIK 2028614 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024-09-302024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $95,689 | $136,934 | $143,301 | $2.09M | $263,703 | $131,919 | $330,925 | $144,928 |
| Operating income | -$95,689 | -$136,934 | -$143,301 | -$2.09M | -$263,703 | -$131,919 | -$330,925 | -$144,928 |
| Net income | $1.24M | $1.73M | $1.97M | $212,958 | $2.18M | $2.29M | $1.25M | -$144,928 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Banking | ||||||||
| Deposits | $300,000 | $300,000 | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17,011 | $20,280 | $14,887 | $6,137 | $717 | $822 | $822 | $2,095 |
| Current assets | $48,991 | $69,184 | $14,887 | $12,191 | $28,196 | $49,726 | $71,019 | — |
| Total assets | $147.46M | $146.90M | $242.04M | $239.92M | $237.63M | $235.21M | $232.81M | — |
| Current liabilities | $2.26M | $2.94M | $492,169 | $376,172 | $456,611 | $301,441 | $347,369 | — |
| Total liabilities | $8.45M | $9.14M | $7.39M | $7.28M | $7.36M | $7.20M | $7.25M | — |
| Shareholders' equity | -$8.40M | -$7.41M | -$7.38M | -$7.26M | -$7.33M | -$7.15M | -$7.18M | -$164,859 |
| Shares outstanding | 10.72M | 10.72M | 10.72M | 10.72M | 10.52M | 10.52M | 10.52M | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$78,269 | -$244,607 | -$91,250 | -$125,180 | -$56,108 | -$106,655 | -$251,244 | — |
| Investing cash flow | -$900,000 | — | — | $0 | $0 | $0 | -$231.15M | — |
| Financing cash flow | $975,000 | -$98.46M | $100,000 | $130,600 | $56,003 | $106,554 | $231.40M | — |
· Financial companies (banks, insurers, …) usually do not report gross profit or operating income; bank revenue is net revenue (net interest income + noninterest income), smaller than "gross interest income + noninterest income".
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.